Hematology

Acalabrutinib plus venetoclax, with or without obinutuzumab, demonstrated significant improvements in progression-free survival.

Investigators determine the efficacy and safety of the combination in a 2-phase trial.

This is the first and only on-demand, virus-inactivated, human plasma-derived concentration option that is indicated for this approval.

The drug previously received breakthrough therapy designation for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia that is in chronic phase.

Early identification of monoclonal gammopathy of undetermined significance leads to more efficacious disease monitoring and intervention.

Increased levels of absolute lymphocyte count are associated with improved response to BCMA-targeted CAR T-cell therapy.

The findings show that those with higher plasma homocysteine concentrations experienced more sleep apnea events per hour compared with those with lower concentrations.

Researchers identify significant proteins involved in the growth and survival of malignant multiple myeloma cells.

Omar Nadeem, MD, discusses positive outcomes associated with GPRC5D-targeted CAR T-cell therapy.

Chimeric antigen receptor (CAR) T-cell therapy can engineer T cells to target malignant cells in multiple myeloma.

Increased immunoglobulin replacement therapy led to reduced infections and managed secondary immune deficiencies such as hypogammaglobulinemia.

Collaboration between community centers and academic medical centers can improve patient access to these complex therapies.

The approval marks the first and only T-cell engaging bispecific antibody administered subcutaneously to treat patients after 2 or more lines of systemic therapy.

Site-of-care considerations can pose challenges with these therapies.

These findings build off research from March 2023 that demonstrated efficacy and safety of renizgamglogene autogedtemcel in patients with sickle cell disease.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, discusses the impact of CAR T cell and bispecific therapies in treatment of patients with hematological malignancies.

Tim Mok, PharmD, BCOP, BCPS, discusses innovative therapies that are changing the treatment options available for patients with hematologic malignancies.

The FDA approved blinatumomab for treatment of patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.

With this approval, Yimmugo is the first approved product from the Biotest Next Level production facility.

Trametinib may become an alternative treatment to hematopoietic stem cell transplantation in patients with relapsed or refractory juvenile myelomonocytic leukemia (JMML).

Brentuximab vedotin in combination with lenalidomide and rituximab had a favorable safety profile for patients with relapsed/refractory diffuse large B-cell lymphoma.

This article provides an overview of data supporting the utility of covalent Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia and details important considerations when choosing among agents.

Individuals with very low- to intermediate-risk myelodysplastic syndromes treated with luspatercept (Reblozyl; Bristol Myers Squibb) achieved improvements in hemoglobulin levels.

After allogeneic stem cell transplantation overall survival and relapse-free survival rates in patients with relapsed or refractory acute myeloid leukemia were 52% and 47%, respectively.

Imetelstat (Rytelo; Geron Corp) is a first-in-class telomerase inhibitor.

According to investigators, the primary and key secondary end points were met during the 52-week placebo-controlled period of the trial.

Asciminib demonstrated stronger efficacy, safety, and tolerability, as well as less adverse events in patients compared with those who received investigator-selected standard-of-care tyrosine kinase inhibitors.

Lisocabtagene maraleucel (Breyanzi; Bristol Myers Squibb) is a CD19-directed CAR T-cell therapy that is delivered as a one-time infusion.

Researchers observed that patients aged 80 years and older with acute myeloid leukemia who were treated with venetoclax and a hypomethylating agent had prolonged overall survival.

The indication is for adult patients who have received at least 2 prior lines of systemic therapy and is based on the response rate and duration of response shown in a phase 2 trial.